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There is currently a strong interest in using high-throughput in-vitro ion-channel screening
data to make predictions regarding the cardiac toxicity potential of a new compound
in both animal and human studies. A recent FDA think tank encourages the use of
biophysical mathematical models of cardiac myocytes for this prediction task. However,
it remains unclear whether this approach is the most appropriate. Here we examine five
literature data-sets that have been used to support the use of four different biophysical
models and one statistical model for predicting cardiac toxicity in numerous species using
various endpoints. We propose a simple model that represents the balance between
repolarisation and depolarisation forces and compare the predictive power of the model
against the original results (leave-one-out cross-validation). Ourmodel showed equivalent
performance when compared to the four biophysical models and one statistical model.
We therefore conclude that this approach should be further investigated in the context
of early cardiac safety screening when in-vitro potency data is generated.
Keywords: cardiac toxicity, mathematical model, ion-channel pharmacology, predictive pharmacology,
biostatistics
Introduction
The consequence of a drug carrying cardiac liability is a significant cause of concern to
the Pharmaceutical industry. In the late 1980s to the early 1990s, a number of significant
withdrawals from market occurred due to the detection of drug induced cardiac arrhyth-
mias, e.g., Torsades de Pointes (ventricular tachycardia) such as prenylamine, lidoflazine,
and terodiline from UK and EU market (Stockbridge et al., 2013). The exact number of
drugs that cause Torsades de Pointes is unknown, however the CredibleMeds initiative
(www.crediblemeds.org) has cataloged 42 drugs with a “Known Risk of Torsades de Pointes.”
These arrhythmias were mostly attributed to drugs causing significant prolongation to the
QTc interval (time taken for ventricular depolarisation and repolaristaion), which is in turn
related to the delay in repolarisation of the ventricular wall. Causative link was then estab-
lished with drug blocking of the hERG (human-ether-a-go-go) ion-channel within ventricu-
lar myocytes (Pollard et al., 2010). As a consequence, routine screening of compounds via
in-vitro high-throughput screening (HTS) devices was quickly incorporated into early stages
of drug-development (Pollard et al., 2010). Initial screens focused only on the hERG chan-
nel but in recent years it has become apparent that other ion-channels might critically
affect cardiac electrophysiology. In particular, hCav1.2 and hNav1.5 have been recognized as
key depolarising ion channels with important roles in the mechanisms causing arrhythmia,
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e.g., long QT syndromes LQT3 and LQT8 syndromes (Lehnart
et al., 2007). Therefore, screenings have now also been extended
to include these other ion-channels (Cavero and Holzgrefe,
2014).
Research efforts have highlighted the potential use of in-silico
biophysical models (Trayanova, 2011) of cardiac myocytes to
predict the cardiac risk in-vivo or even in the clinical setting,
based on in-vitro ion-channel screening data (Cavero and Holz-
grefe, 2014). These models describe the dynamic opening and
closing of ion-channels and resulting temporal variation of cell
Action Potential (AP) via a set of differential equations. They are
parameterized based on experimental data from electrophysio-
logical recordings of isolated ion-channels and also whole cell AP
recordings. Their goal is generally to produce a descriptive model
of the cardiac myocyte which is then used to better understand
general cardiac biology. Nevertheless, there is still uncertainty as
to whichmodel is best suited to assist in cardiotoxicity prediction.
Answering these questions is in line with recent initiatives
from a FDA sponsored think tank suggesting the usage of in-
silico tools in correlating non-clinical in-vitro studies with proar-
rhythmic risk (Sager et al., 2014). Two techniques have been
used in the literature: (1) biophysical models which describe the
dynamics of a cardiac myocyte through differential equations of
which there are 4 examples (Mirams et al., 2011, 2014; Davies
et al., 2012; Beattie et al., 2013) and (2) statistical models which
focus on known ion-channel pharmacology of which there is only
one literature example (Kramer et al., 2013). Here we investi-
gate an alternative strategy based on a one-equation classifier
model and show that similar predictive power can be obtained
with this strategy. In particular, we highlight the capacity of such
a model in handling all datasets, in contrast with the original
studies where a specific model was used at each time. The mod-
els predictive power within each data-set under consideration is
also assessed via a leave-one-out cross validation exercise where
an optimal parameter set for each data-set is used. We will then
discuss the advantages of this alternative approach.
Materials and Methods
Data-Sets
All data-sets are reported in the Supplementary Material. Here
we present a brief summary:
• Human 1 (Kramer et al., 2013) contains 55 compounds and
assessed the Torsades de Pointes risk of each compound. All
ion-channel potency data was generated from two in-vitro
HTS platforms, Qpatch, and PatchXpress. The cell lines used
were HEK293 and CHO (Chinese Hamster Ovary). The in-
silico model used within that study was a statistical (logistic
regression) model which classified a compound as posing a
Torsades de Pointes risk or not.
• Human 2 (Mirams et al., 2011) contains 31 compounds and
assessed the Torsades de Pointes risk of each compound. Ion-
channel potency data was derived from numerous literature
in-vitro reports. The in-silico model used within that study
was a biophysical model (39 differential equations) which clas-
sified compounds into one of four Torsades de Pointes risk
categories. This was then simplified to a binary classification
question of whether a compound posed a Torsades de Pointes
risk or not.
• Human 3 (Mirams et al., 2014) contains 34 compounds and
assessed the QTc prolongation potential of each compound.
We investigated the data-set which gave the authors the best
result. This contained in-vitro hERGmanual patch-clamp data
(obtained from regulatory documents for each compound)
and in-vitro HTS data for the other ion-channels (IonWorks
Quattro using CHO cells). The in-silico model used within
that study was a biophysical model (41 differential equations)
which classified compounds as QTc prolongers or not at the
mean drug concentration. QTc prolongation was defined by a
mean increase in QTc interval of at least 5ms.
• Dog (Davies et al., 2012) contains 53 compounds and assessed
the time taken for the canine AP duration to repolarise by 90%
(APD90) within the canine AP in-vitro assay. All ion-channel
potency data was generated from the same in-vitro HTS plat-
form, IonWorks\FLIPR with CHO cells. The in-silico model
used within that study was a biophysical model (29 differen-
tial equations) which classified compounds to one of three
categories: prolongation, shortening or no effect. Prolonga-
tion/shortening was defined by a greater than 10% change in
either direction compared to control at a given drug concen-
tration.
• Rabbit (Beattie et al., 2013) contains numerous data-sets with
potency estimates generated from different platforms (in-vitro
and in-silico i.e., computational chemistry predicted potency
estimates) and assessed the change in QTc within the ex-vivo
rabbit ventricular wedge assay. Here we considered the dataset
that gave the authors the best result there. This contained a
total of 77 compounds where all the ion-channel potency data
was generated from the same in-vitro HTS platform, PatchX-
press with HEK293 and CHO cells. The in-silico model used
within that study was a biophysical model (45 differential
equations) which classified compounds in the same way as the
above dog study.
Drug Effect
The ion-channel screening data extracted from the articles was
converted into block or agonism of an ion-channel at a given drug
concentration of interest in the following way. We first defined
the effect S of a drug on ion-channel x as:
Sx = 1−
1
1+
(
IC50
[D]
)n ,
for an inhibitor and
Sx = 1+
Emax
1+
(
EC50
[D]
)n ,
for an agonist, where x = IKr , x = ICaL or x = INa refer to the
hERG, hCav1.2, and hNav 1.5 ion-channels respectively, [D] is
the concentration of drug, IC50 is the amount of drug required to
reduce the effect by 50%, EC50 is the amount of drug required
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to increase the effect by Emax/2, Emax the maximum effect of
an agonist and n the hill coefficient. The IC50, EC50, Emax, and
n values were taken as per the published data-sets. There, drug
effects within bio-physical models were modeled by scaling con-
ductances of ion-channels by Sx which was also done here. Only
effects against the above three ion-channels were considered as
they were consistently measured across all studies.
One-Equation Classifier Model
It is well understood that the hERG channel is responsible for
repolarisation and that hCav1.2 and hNav1.5 ion-channels are
largely responsible for depolarisation of the action potential.
We hypothesized that the balance between the block/agonism
of depolarisation and repolarisation forces is the main parame-
ter driving drug effects’ predictions. The following classifier was
suggested:
Z =
1+ a0SCaL + a1SNa
1+ a2SKr
where a0, a1, and a2 are coefficients that need to be determined.
For simplicity, we initially chose to set the coefficients in the
model to 1, as the first goal of this study was to assess the
discriminatory value of the model without specific parameters
optimization.
ROC Curve
The model was initially assessed through a receiver operating
characteristic (ROC) curve analysis (Zou et al., 2007). The ROC
curve is a plot of the sensitivity (true positive rate) as a function
of 1—specificity (i.e., false positive rate) for different cut-off val-
ues of a discriminant variable. The ROC curve can be assessed
by looking at the obtained area under the curve (AUC). A value
equal to 1 implies 100% sensitivity/specificity while a value equal
to 0.5 represents 50% sensitivity/specificity. The ROC curve can
also be inspected visually by comparing it to the line of unity: the
further the curve is above this line the better.
Within this analysis, the following binary classification ques-
tions were asked:
(1) For the dog and rabbit data-sets:
(a) Does a compound cause prolongation?
(b) Does a compound cause shortening?
(2) For human 1 and 2 data-sets, does a compound have a
Torsades de Pointes risk or not [definitions as per original
articles (Mirams et al., 2011; Kramer et al., 2013)]?
(3) For human 3 data-set, does a compound cause QTc prolon-
gation?
For the animal data-sets the above setup does mean a compound
can be classified as both prolongation and shortening, however
this is relaxed when considering the predictivity of the model as
described below.
Leave-One-Out Cross Validation
After assessing the structural models discriminatory value
through a ROC analysis we assessed the predictive power of the
model via a leave-one-out cross validation. We used n − 1 com-
pounds to train the model and the nth compound to test it.
This process was repeated until all n compounds were used as
a test-set. Here the model parameter values, a0, a1, and a2, were
optimized for each data-set (see Supplementary Material). Com-
pounds within the animal data-sets were classified as causing
prolongation, no-effect or shortening. The result of this analy-
sis was summarized through sensitivity, specificity and balanced
accuracy [i.e., (sensitivity+ specificity)/2] metrics. These metrics
were then compared to the reported results of the original articles
model predictions.
Results
ROC Analysis and Model Comparison
Overall it can be seen (Figure 1) that the ROC curve for the five
cases investigated sit comfortably above the identity line. This
shows that the model demonstrates good discriminatory power
for all datasets without data-set specific parameter optimization.
The strongest result can be seen for assessing whether a com-
pound has a Torsades de Pointes risk or not (bottom left graph
of Figure 1). The AUC values of the ROC curves for human 1
(dashed line) and 2 (solid line) data-sets are 0.94 and 0.96, respec-
tively. These values are considered to be excellent and are close
to a perfect classifier. The signal for QTc prolongation was also
found to be good (ROC AUC of 0.72). The model also performed
well for the animal data-sets: the ROC AUC values for dog and
rabbit prolongation were 0.72 and 0.84 respectively, while the
AUC values for shortening were 0.63 and 0.72 respectively.
We then performed a leave-one-out cross validation where
model parameters were allowed to vary and an optimum set
derived for each data-set. The results of this additional analy-
sis and comparison of our model’s prediction to the reported
predictions can be seen in Table 1. Our model results were over-
all comparable to the published models’ results. Sensitivity was
increased in all data-sets except the Human 1 and 2 data-sets
where the difference was minimal. Specificity was in good agree-
ment against all the literature models. The balanced accuracy
was either equal or improved over the current published mod-
els except in the Human 2 data-set where our model performed
slightly worse than the biophysical model used there.
Discussion
There is currently strong interest from both regulatory agencies
and pharmaceutical companies in the use of in-silico mod-
els of cardiac myocytes as a tool for integrating the car-
diac ion-channel liability of new compounds. This interest is
motivated by the question of predicting the effects of a new
compound’s cardiac risk in animal or man simply by using
in-vitro ion-channel potency data (Cavero and Holzgrefe, 2014).
This question has been predominantly answered to date by
either empirically defining cut-off thresholds for IC50 values or
by using in-silico approaches with biophysical models (Mirams
et al., 2011, 2014; Davies et al., 2012; Beattie et al., 2013). Only
one statistical model approach have been used to date to our
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FIGURE 1 | Top left graph, dog data-set: ROC curve for
prolongation (solid line) and for shortening (dashed line). Top right
graph, rabbit data-set: ROC curve for prolongation (solid line) and for
shortening (dashed line). Bottom left graph: ROC curve for Torsades de
Pointes risk for the human 1 (dashed) and human 2 (solid) data-sets.
Bottom right graph: ROC curve for QTc prolongation for the human 3
data-set (solid). In all graphs the thin solid line represents a ROC curve
of random chance.
TABLE 1 | Sensitivity, specificity, and balanced accuracy of our model compared with the original models’ predictions.
Data-set
Binary Test Question (Yes/No)
Sensitivity% Specificity% Balanced Accuracy%
This model Original model This model Original model This model Original model
Human 1
Torsade de Pointes Risk
97 97 91 83 94 90
Human 2
Torsade de Pointes Risks
93 100 97 97 95 98.5
Human 3
QTc Prolongation
57 50 90 85 73.5 67.5
Rabbit
Prolongation
96 72 73 81 84.5 66.5
Rabbit
Shortening
50 31 87 80 67.5 60
Dog
Prolongation
67 60 84 76 75.5 68
Dog
Shortening
67 48 78 87 72.5 67.5
Better metrics are highlighted in green. Worse metrics are highlighted in red.
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knowledge (Kramer et al., 2013). Biophysical models benefit
by incorporating representations of cardiac myocyte biology
that may provide an intuitive leap for the experienced elec-
trophysiologist to articulate depolarization mechanisms. Indeed,
there are now many models representing different cell types
and species available (see for instance the CellML database
http://models.cellml.org/cellml).
Nevertheless, these biophysical models can suffer from
their size and display complex behavior which can be highly
parameter-sensitive (Gutenkunst et al., 2007). Their formulations
vary greatly between species and cell-type and there are also com-
peting formulations for the same species and cell-type. It is dif-
ficult to fully validate such models in practice. Moreover, this
pre-existing complexity can be compounded by the additional
incorporation of other major biological processes such as drug
binding kinetics, regulatory signaling or spatio-temporal effects
as well as statistical assessment. Thus, we wanted to explore how
a model that minimizes mathematical formulation to describe
AP prolongation compares to biophysical models in its predic-
tive capacity. Such a tool, which is far less complex than current
biophysical models, could facilitate the additional incorporation
of other fundamental processes (Lu et al., 2013) and of statistical
considerations (Chain et al., 2011).
We introduced a new classifier-type model, which is relatively
simple (one equation) and can be directly interpreted in terms of
the balance between depolarisation and repolarisation forces. The
model performance was assessed via a ROC analysis and a leave-
one-out cross validation across various literature data-sets.When
comparing this model performance against published biophysical
models, we found comparable results (same scoring system as per
original studies was used). As a consequence, these results sug-
gest that biophysical models might not provide significant benefit
over the approach taken here to describe the correlation between
ion-channel block and compound risk. It is possible that these
models may be better suited to understand and articulate the
cellular and tissue processes mechanistically, without having nec-
essarily reached the required maturity that would imply added
benefit in terms of predictive pharmacology.
With our new approach, other biological processes can be
also incorporated by emphasizing on their influence rather than
their precise mathematical description. The influence of other
ion channels such as Ik1, INaCa, Ito or IKs can be incorporated
in similar ways as per the ion-channels considered here. We
can also imagine the possibility of accounting for slow vs. fast
ion-channel block with additional parameters. New approaches
have indeed emerged recently to elucidate drug binding dynam-
ics using modern HTS assays (Di Veroli et al., 2013, 2014). Other
processes such as spatio-temporal effects or regulatory processes
can be integrated as separated factors and could also account for
variability across populations. Furthermore, a simple model like
this is easier to implement for scientists of all backgrounds and
does not require extensive amount of domain specific knowledge.
It can potentially lead to both cost and time-savings for safety
pharmacology groups who are interested in assessing ion-channel
related cardiac toxicity risk of new compounds.
All mathematical models, either simple or complex, might be
followed later on by experiments to test for cardiac safety screen-
ing. Nevertheless, they represent a valuable tool for assessing
risk and prioritizing new compounds at early stages. Biophysi-
cal models explicitly describe the mechanisms behind AP prop-
agation and other important biological processes and are thus
invaluable for gaining qualitative understanding of biological
processes. Although our simple model does not claim to provide
the level of description given by biophysical models, our results
showed similar predictive power when correlating ion-channel
block with AP or QT prolongation/shortening using published
datasets. At the same time, ourmodel was applied across different
species and also avoided model complexity and its inherent risks.
Thus, we propose this approach to form the basis of data-driven
systems pharmacology strategies as it simplifies the incorporation
of other aspects such as uncertainty and biological variability.
Being able to include uncertainty is indeed a key hallmark of sim-
ple models compared to larger models as it is easier to place such
model within a statistical framework.We hope that these surpris-
ing but significant results indicate how different model strategies
can be used inclusively and can help the researcher in under-
standing the limitations in prediction over different modeling
scales.
Supplementary Material
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/journal/10.3389/fphar.
2015.00059/abstract
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